Cambridge, UK: o2h discovery is pleased to announce the launch of o2h Biology Match Funding, a unique programme aimed at accelerating drug discovery research by offering to match fund 50% of the cost for biology research projects up to $65K/£50K in value. This initiative presents an exciting opportunity for biotechs of all sizes and pharma to achieve key scientific milestones, helping to advance their drug discovery programmes.

The o2h Biology Match Funding Programme not only supports your biology project at 50% costs but also enables participants to tap into o2h’s vast expertise and resources, ensuring the delivery of impactful scientific results. With this initiative, we aim to foster a collaborative environment that drives scientific breakthroughs and promotes growth within the biotech ecosystem.

The Match Funding award will help winners leverage o2h discovery’s multi-modality integrated drug discovery platform, operating from its state-of-the-art research facilities in Cambridge, UK, and Ahmedabad, India. With a comprehensive range of biology services including Target Engagement, Assay Development, Drug Screening, and Cell-Based Assays, o2h is well-positioned to support groundbreaking research. Our suite of biological capabilities includes label and label-free screening platforms, suitable for low- to medium-throughput projects, making us a key partner for hit identification across various therapeutic areas.

Gayathri Sadasivam, Vice President – Biology, o2h discovery, said:

“The o2h Biology Match Funding program offers a unique opportunity for pioneering companies in pre-clinical drug discovery and development. At o2h, we are committed to scientific excellence. We have a highly experienced team with the right expertise that can be tailored to specific research needs, enabling us to work collaboratively by becoming a part of your drug discovery endeavours.

Our skills, coupled with the state-of-the-art technology platforms can facilitate faster problem solving for your diverse drug discovery programs. I am looking forward to working with biotechs and pharma on their exciting science!”

o2h discovery brings over two decades of scientific expertise to every project, offering a strong foundation for researchers tackling complex biology challenges. Our team has developed and published specialised assays across diverse domains, including ChamelogK, Psychedelic Assays, Integrin Assays, and PROTAC studies. With our deep knowledge base, we are dedicated to helping researchers unlock potential breakthroughs.

Prashant Shah, CEO and Co-Founder, o2h discovery, said:

“‘From Idea to Data’ – We are excited to announce the launch of the o2h Biology Match Funding Programme—a bold step towards collaborating with biotechs and pharma to ‘move’ novel drug discovery research from ideas in the mind or on paper and onto the bench generating data. In o2h, we love seeding new ideas in life sciences and we are extending a generous offering to match up to 50% of the cost for biology research projects. Award winners will gain access to extensive biology capability in o2h discovery operating from our state-of-the-art research facilities in Cambridge, UK and Ahmedabad, India.”

The o2h Biology Match Funding Award is open to all sizes of biotech companies, big pharma, and academic institutions with novel drug discovery programs requiring biology research support. Startups that have secured initial funding are also eligible. All projects must be conducted exclusively at o2h discovery in-house facilities, and project costs must not exceed $65K/£50K. Each application will be evaluated by the evaluation committee consisting of highly experienced biologists and medicinal scientists, who will assess the project’s scientific potential, scope, team, impact on human health, alignment with o2h’s capabilities, amongst other things.

For more information and to apply, please visit: https://o2hdiscovery.co/biology-match-funding or email us at biologymatchfund@o2h.com

Editor Notes: 

About o2h discovery: 

Founded in 2004, o2h discovery has a multi-modality integrated drug discovery platform, operating from Cambridge, UK, and Ahmedabad, India. We have the in-house capabilities to execute hit-lead optimisation programs leading into the patent and IND filing from our state-of-the-art biotechnology incubator with expertise in discovery chemistry, biology, pharmacology, and the ongoing project management of preclinical development.

Our proven track record of working with “me too” and “undruggable” class of targets. This coupled with a good understanding of potency to efficacy translation, we provide an integrated suite of high-quality biophysical, biochemical & cellular-assay platforms.

For more information, visit: https://o2hdiscovery.co or email discovery@o2h.com